The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
- Martin J. van den Bent*
- , Pim J. French
- , Daniel Brat
- , Joerg C. Tonn
- , Mehdi Touat
- , Benjamin M. Ellingson
- , Robert J. Young
- , Johan Pallud
- , Andreas von Deimling
- , Felix Sahm
- , Dominique Figarella Branger
- , Raymond Y. Huang
- , Michael Weller
- , Ingo K. Mellinghoff
- , Tim F. Cloughsey
- , Jason T. Huse
- , Kenneth Aldape
- , Guido Reifenberger
- , Gilbert Youssef
- , Philipp Karschnia
*Corresponding author for this work
- Northwestern University
- Ludwig Maximilian University of Munich
- German Cancer Research Center
- Harvard Medical School
- Sorbonne Université
- David Geffen School of Medicine
- Memorial Sloan-Kettering Cancer Center
- Institute of Psychiatry and Neuroscience of Paris
- Service de Neurochirurgie
- Aix-Marseille Université
- Harvard University
- University of Zurich
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (Bethesda, Md)
- Universitätsklinikum Düsseldorf
- Dana-Farber Cancer Institute
- Michigan State University
- Duke University
- University Lyon 1
- Hospices Civils de Lyon
- Medical University of Vienna
Research output: Contribution to journal › Review article › Academic › peer-review
48
Citations
(Scopus)
69
Downloads
(Pure)